The EVP & GC of Exelixis (NASDAQ: EXEL) is Selling Shares


Yesterday, the EVP & GC of Exelixis (NASDAQ: EXEL), Jeffrey Hessekiel, sold shares of EXEL for $447.2K.

In addition to Jeffrey Hessekiel, 3 other EXEL executives reported Sell trades in the last month. Following Jeffrey Hessekiel’s last EXEL Sell transaction on April 30, 2018, the stock climbed by 1.4%.

See today’s analyst top recommended stocks >>

Based on Exelixis’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $212 million and quarterly net profit of $116 million. In comparison, last year the company earned revenue of $80.89 million and had a net profit of $16.64 million. EXEL’s market cap is $6.66B and the company has a P/E ratio of 27.42. Currently, Exelixis has an average volume of 2.73M.

Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $34.50, reflecting a -35.6% downside.

In the last 30 days, insiders have sold $1.39M worth of EXEL shares and purchased $76.5K worth of EXEL shares. The insider sentiment on Exelixis has been negative according to 49 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts